halofuginone has been researched along with Keloid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatelain, B; Dirand, Z; Humbert, P; Isidoro, C; Lihoreau, T; Marty, P; Rolin, G; Secomandi, E; Senez, C; Tissot, M | 1 |
| Emanuele, E; Lista, S | 1 |
2 other study(ies) available for halofuginone and Keloid
| Article | Year |
|---|---|
Halofuginone regulates keloid fibroblast fibrotic response to TGF-β induction.
Topics: Actins; Adult; Cell Movement; Cell Proliferation; Cells, Cultured; Collagen Type I; Extracellular Matrix; Female; Fibroblasts; Fibrosis; Humans; Keloid; Male; Middle Aged; Myofibroblasts; Piperidines; Procollagen; Quinazolinones; Skin; Transforming Growth Factor beta1; Young Adult | 2021 |
Potential therapeutical effects of topical halofuginone hydrobromide in keloid management.
Topics: Administration, Topical; Cell Proliferation; Gene Expression Regulation, Enzymologic; Humans; Keloid; Matrix Metalloproteinase 2; Models, Biological; Models, Theoretical; Piperidines; Protein Synthesis Inhibitors; Quinazolinones | 2007 |